Global CAR T Cell Therapy Clinical Pipeline Report 2022-2028: Pharma Giants are Increasingly Partnering/Collaborating with Technology Companies to Integrate Advanced Technologies

17 Jun 2022
www.prnewswire.com
Financial StatementCell TherapyImmunotherapy
DUBLIN, June 17, 2022 /PRNewswire/ -- The "Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2028" drug pipelines has been added to
ResearchAndMarkets.com's offering.
Global CAR T cell therapy market opportunity is expected to surpass US$ 15 Billion by 2028
The development of CAR TCAR T cell therapy will gather momentum from the increasing number of investors, designers, and analysts in the guide therapy.
Rising frequencies of cancer across the globe together with the relentless technological advancement for dependable and effective cancer treatment is expected to support the growth of the worldwide CAR-T cell therapy market. Furthermore, heavy investments in clinical research and development in cell therapy are estimated to boost the market for CAR-T cell therapy in the years to come.
The report provides information on the globally approved CAR T cell therapies along with their price, dosage, and sales analysis. The report analyzes and forecasts the size of the global CAR-T cell therapy market.
The report delivers a full-scale exploration of market dynamics and factors that are manipulating the growth of the global CAR-T cell therapy market. The report also gives a competitive analysis of major market players that will give a competitive advantage to customers in their respective businesses.
Chimeric antigen receptor (CAR) T cell therapy is a novel immunotherapeutic approach that is indicated for the management of cancer. CAR T-cell therapy is a type of therapy in which the T-cells are taken from the blood of the patient, which is then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor).
This aids in better recognizing of specific cancer cell antigens. The CAR T-cells are then given back to the patient. To date, 6 CAR T-cell therapy products including Kymriah (tisagenlecleucel), yescarta (axicabtagene), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), and Abecma (idecabtagene vicleucel) have been approved by FDA for the management of wide range of cancers. In addition to this, Relmacabtagene autoleucel have been approved in China.
The introduction of CAR T cell therapies has shown high adoption rates in a short span of time has propelled further research and development activities in this domain. Apart from hematological malignancies, the researchers are also expanding the role of CAR T cell therapies in solid tumors which will propel the growth of the market.
For instance, a recent research study demonstrated that infusing immune cells into patients has shown early promise by shrinking tumors in digestive system. The interim results demonstrated that tumors in nearly 50% of the 37 patients so far reduced in size after the therapy.
The global CAR T cell therapy market is highly consolidated with several key players. The pharmaceutical giants in the market are increasingly partnering or collaborating with technology companies to integrate advanced technologies for the betterment of CAR-T therapy or to expand their geographical presence.
For instance, Bayer and Atara Biotherapeutics entered into a worldwide license agreement for the development of next-generation ATA3271 which is mesothelin-directed CAR-T cell therapy. The agreement also aims to develop ATA2271, for the management of high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.
Among drug types, Yescarta is currently dominating the market. Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma.
Recently in 2022, regulatory bodies expanded the approval of drugs for the management of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy. The wide range of therapeutic indications as well as the global availability of the drug is the major factors which are the major factors aiding in the dominance of these factors.
Report Highlights:
Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
Global & Regional Market Insight: Current & Market Forecast 2028
Approved CAR T Cell Therapies Sales Forecast Till 2028
Emerging In Vivo Induced CAR T Cell Therapies
CAR T Cell Therapy Manufacturing Cost Analysis
CAR T Cell Therapy Approval & Reimbursement Scenario By Country
Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies
Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase
Key Topics Covered:
2. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology
3. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
3.1 Structure of CAR-T Cell
3.2 1st Generation Chimeric Antigen Receptor
3.3 2nd & 3rd Generation CAR-T Cell
3.4 Principle of Chimeric Antigen Receptor Design
4. Approaches to Improve the Efficiency of CAR-T Cell Therapy
5. CAR T CellT Cell Therapy Manufacturing Cost Analysis
6. Emerging In-Vivo Induced CAR T Cell Therapies
6.1 Need of In-Vivo CAR T Cell Therapy
6.2 In-Vivo CAR T Cell Platform; VivoVec, TumorTag, & RACR/CAR
6.3 Key Drug in Research & Development
7. Global CAR T Cell Therapy Market Outlook 2022 - 2028
7.1 Market Overview
7.2 Future Market Opportunity
8. Globally Approved CAR T Cell Therapies - Pricing, Dosage & Sales Analysis 2028
8.3 Brexucabtagene Autoleucel (Tecartus)
8.4 Lisocabtagene maraleucel (Breyanzi)
8.6 Relmacabtagene autoleucel (Carteyva)
9. US CAR T Cell Therapy Market Outlook
9.1 Approved & Key CAR T Cell Therapy Products in US
9.2 Market Overview
9.3 Current Reimbursement Scenario
10. Europe CAR T Cell Therapy Market Outlook
10.1 Approved & Key CAR T Cell Therapy Products in Europe
10.2 UK
10.3 Germany
10.4 Spain
10.5 France
10.6 Rest of Europe
10.7 Current Reimbursement Scenario
11. China CAR T Cell Therapy Market Outlook
11.1 Approved & Key CAR T Cell Therapy Products in China
11.2 Current Market Size & Forecast
12. Japan CAR T Cell Therapy Market Outlook
12.1 Approved & Key CAR T Cell Therapy Products in Japan
12.2 Market Overview
12.3 Current Reimbursement Scenario
13. South Korea CAR T Cell Therapy Market Outlook
13.1 Approved & Key CAR T Cell Therapies in South Korea
13.2 Future Market Opportunity
14. Australia CAR T Cell Therapy Market Outlook
14.1 Approved & Key CAR T Cell Products in Australia
14.2 Australia CAR T Cell Therapy Market
14.3 Current Reimbursement Scenario
15. Taiwan CAR T Cell Therapy Market Outlook
16. Global CAR T Cells Clinical Pipeline Overview
16.1 By Company
16.2 By County
16.3 By Indication
16.4 By Phase
17. Global CAR T Cells Clinical Pipeline By Company, Indication & Phase
17.1 Research
17.2 Preclinical
17.3 Clinical
17.4 Phase-I
17.5 Phase-I/II
17.6 Phase-II
17.8 Registered
18. Marketed CAR T Cell Therapy Clinical insight
18.1 Breyanzi
18.3 Yescarta
18.4 Kymriah
18.5 Abecma
19. Global CAR-T Cell Therapy Market Dynamics
19.1 Favorable Parameters
19.2 Market Challenges
20. Competitive Landscape
20.1 Autolus
20.4 Celgene
20.6 Celyad
20.12 Novartis
20.13 Sorrento therapeutics
20.15 Ziopharm
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lwj8p4
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.